---
title: CDMO Daily News — November 20, 2026
slug: daily-news-2026-11-20-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: November 20 CDMO daily: Gene2Cure Collaborates with Viralgen to Manufacture Gene Therapies for Rare Diseases; OXB Partners with Aura Biosciences for Phase 3…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-11-20-cdmo
published_at: 2026-11-20T00:00:22.321Z
last_updated: 2026-11-20T00:01:59.992Z
---

### Gene2Cure Collaborates with [Viralgen](/companies/viralgen) to Manufacture Gene Therapies for Rare Diseases
- Gene2Cure Foundation has partnered with [Viralgen](/companies/viralgen) to manufacture investigational gene therapies for rare genetic diseases.
- Viralgen will utilize its Aava platform for AAV manufacturing services, supporting both toxicology studies and clinical use.

**Operational Impact**

This collaboration enhances [Viralgen](/companies/viralgen)'s role in gene therapy manufacturing, potentially increasing capacity for rare disease treatments.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/gene2cure-partners-with-viralgen-to-advance-three-rare-disease-gene-therapy-programs)*

---

### [OXB](/companies/oxb) Partners with Aura Biosciences for Phase 3 Manufacturing of Ocular Cancer Therapy
- [OXB](/companies/oxb) has confirmed a manufacturing partnership with Aura Biosciences for belzupacap sarotalocan, an investigational therapy for ocular cancers.
- The collaboration will utilize OXB’s facilities in Bedford, Massachusetts, and Durham, North Carolina, for process performance qualification and commercial production.

**Operational Impact**

This partnership allows [OXB](/companies/oxb) to expand its manufacturing capabilities into virus-like drug conjugates while supporting Aura's late-stage clinical development.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/oxb-confirms-manufacturing-partnership-with-aura-biosciences-for-phase-3-cancer-therapy)*

## References

1. [PharmaSource RSS — Gene2Cure Collaborates with Viralgen to Manufacture Gene Therapies for Rare Diseases](https://pharmasource.global/content/news/cdmo-news/gene2cure-partners-with-viralgen-to-advance-three-rare-disease-gene-therapy-programs)
2. [PharmaSource RSS — OXB Partners with Aura Biosciences for Phase 3 Manufacturing of Ocular Cancer Therapy](https://pharmasource.global/content/news/cdmo-news/oxb-confirms-manufacturing-partnership-with-aura-biosciences-for-phase-3-cancer-therapy)

Source: https://www.cdmo.directory/posts/daily-news-2026-11-20-cdmo